{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} At Last, A Brightening Outlook for Chronic GVHD

Activity Steps

1 Activity
2 Take Test 3Certificate

Purpose of Activity

To provide information on a new treatment for chronic GVHD.

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Describe major changes in the diagnosis, classification, and grading of chronic graft-versus-host-disease (GVHD).
  2. Examine the use of ibrutinib to prevent or treat GVHD

Disclosures

All authors, faculty, staff, and planners, including spouses/partners (if any), in any position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity.

Price: $12.95

Credits:

  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • KY-BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223. Your certificate is valid in all states.







Planner
Test Code: OT0717
Published: Jul 2017
Expires: 12/31/2026
Sources: Oncology Times
Required Passing Score: 7/10 (70%)
Authors: Michelle Perron
Categories: Advanced Practice Nursing , Cancer , Oncology
Specialties: Oncology
Topics: Graft-Versus-Host-Disease (GHVD)